CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 102 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2018. The put-call ratio across all filers is 2.89 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $474,000 | -19.5% | 203,304 | -2.0% | 0.00% | 0.0% |
| Q4 2017 | $589,000 | +6.7% | 207,368 | +7.5% | 0.00% | 0.0% |
| Q3 2017 | $552,000 | +4.2% | 192,971 | -10.0% | 0.00% | 0.0% |
| Q2 2017 | $530,000 | -21.9% | 214,400 | +13.9% | 0.00% | 0.0% |
| Q1 2017 | $679,000 | -2.4% | 188,200 | -4.3% | 0.00% | 0.0% |
| Q4 2016 | $696,000 | -14.8% | 196,700 | -2.8% | 0.00% | -50.0% |
| Q3 2016 | $817,000 | -7.2% | 202,300 | +0.9% | 0.00% | 0.0% |
| Q2 2016 | $880,000 | +11.5% | 200,400 | -4.0% | 0.00% | 0.0% |
| Q1 2016 | $789,000 | -72.4% | 208,651 | +14.3% | 0.00% | -71.4% |
| Q4 2015 | $2,862,000 | +51.2% | 182,509 | +1.6% | 0.01% | +40.0% |
| Q3 2015 | $1,893,000 | -58.3% | 179,563 | -0.2% | 0.01% | -54.5% |
| Q2 2015 | $4,536,000 | -9.2% | 179,863 | +0.4% | 0.01% | -8.3% |
| Q1 2015 | $4,994,000 | +64.3% | 179,178 | +7.6% | 0.01% | +71.4% |
| Q4 2014 | $3,040,000 | +42.2% | 166,578 | +1.0% | 0.01% | +40.0% |
| Q3 2014 | $2,138,000 | -19.7% | 164,973 | +1.1% | 0.01% | -28.6% |
| Q2 2014 | $2,662,000 | -7.0% | 163,136 | +0.7% | 0.01% | -12.5% |
| Q1 2014 | $2,863,000 | -26.7% | 162,036 | +0.4% | 0.01% | -27.3% |
| Q4 2013 | $3,908,000 | -24.2% | 161,436 | +11.0% | 0.01% | -26.7% |
| Q3 2013 | $5,153,000 | +134.2% | 145,436 | +3.2% | 0.02% | +114.3% |
| Q2 2013 | $2,200,000 | +35.6% | 140,922 | +0.6% | 0.01% | +40.0% |
| Q1 2013 | $1,622,000 | – | 140,075 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Byrne Asset Management LLC | 86 | $2,000 | 0.00% |